South Korea’s leading clinical diagnostics company, GC Labs has revealed its plan to further expand its operations into the Middle East in line with the increase in demand for genetics and infectious disease tests in the region.
Currently, GC Labs offers its services in Saudi Arabia and the UAE and the company is in talks with regional partners to expand its services to more countries in the Middle East.
In order to create further awareness of its services, GC Labs will participate in the 2022 edition of the leading laboratory and flagship exhibition and conference, Medlab Middle East at Dubai World Trade Centre (DWTC) from January 24 to 27.
During the event, GC Labs will emphasize its “smart lab” concept that offers an automated test system to improve the speed and efficiency of tests, enabling the company to report results in just a day or two.
“The Middle East is an important market for us, and participating in Medlab will help us to share our best practices in clinical diagnostics with the regional health community. Over the past two decades, the world has achieved important success in the fight against pandemics like COVID-19 and in mobilizing global response against HIV-Aids, TB, Malaria and other infectious diseases. Medical laboratories play a key role in this fight by providing high-quality diagnostic testing and by working in partnership with the health authorities.”
GC Labs will host its seminar on ‘Public-Private Partnership in Global Health: bringing the best of both worlds to improve testing’ on 25th January at the Bubble Lounge in Medlab.
GC Labs is South Korea’s leading clinical laboratory, a specialist in infectious diseases, and serves as part of the Global Diagnostics Network. Around 800 employees at GC Labs offer more than 5,000 tests and test combinations, ranging from routine tests to highly esoteric molecular and genetic assays. By entering a Lab Service Agreement with different countries such as Sri Lanka, Vietnam, Myanmar, Indonesia, India and UAE, GC Labs has managed to expand overseas.